Newly Acquired Infection With Multidrug-Resistant HIV-1 in a Patient Adherent to Preexposure Prophylaxis.
作者信息
Markowitz Martin, Grossman Howard, Anderson Peter L, Grant Robert, Gandhi Monica, Horng Howard, Mohri Hiroshi
机构信息
*The Aaron Diamond AIDS Research Center, an Affiliate of the Rockefeller University, New York, NY †Cleveland Clinic Florida, Weston, FL ‡University of Colorado Anschutz Medical Campus, Aurora, CO §Gladstone Institutes, University of California, San Francisco, San Francisco, CA.
出版信息
J Acquir Immune Defic Syndr. 2017 Dec 1;76(4):e104-e106. doi: 10.1097/QAI.0000000000001534.
Abstract
摘要
相似文献
1
Newly Acquired Infection With Multidrug-Resistant HIV-1 in a Patient Adherent to Preexposure Prophylaxis.一名坚持暴露前预防的患者新感染多重耐药HIV-1
J Acquir Immune Defic Syndr. 2017 Dec 1;76(4):e104-e106. doi: 10.1097/QAI.0000000000001534.
2
Multidrug-Resistant HIV-1 Infection despite Preexposure Prophylaxis.尽管进行了暴露前预防但仍出现多重耐药HIV-1感染
N Engl J Med. 2017 Feb 2;376(5):501-502. doi: 10.1056/NEJMc1611639.
3
Acquisition of Multidrug-Resistant Human Immunodeficiency Virus Type 1 Infection in a Patient Taking Preexposure Prophylaxis.接受暴露前预防的患者感染多重耐药人类免疫缺陷病毒 1 型。
Clin Infect Dis. 2018 Aug 31;67(6):962-964. doi: 10.1093/cid/ciy321.
4
Transmission of integrase strand-transfer inhibitor multidrug-resistant HIV-1: case report and response to raltegravir-containing antiretroviral therapy.整合酶链转移抑制剂耐药的HIV-1传播：病例报告及对含raltegravir抗逆转录病毒疗法的反应
Antivir Ther. 2011;16(2):253-6. doi: 10.3851/IMP1748.
5
Transmission of HIV-1 variants resistant to the three classes of antiretroviral agents: implications for HIV therapy in primary infection.对三类抗逆转录病毒药物耐药的HIV-1变异株的传播：对初次感染时HIV治疗的影响
AIDS. 2002 Feb 15;16(3):507-9. doi: 10.1097/00002030-200202150-00034.
6
First report of transmission of a highly resistant strain of HIV-1 group O.首例O组高耐药性HIV-1毒株传播的报告。
AIDS. 2016 Oct 23;30(16):2565-2568. doi: 10.1097/QAD.0000000000001253.
7
Phylogenetic inferences on HIV-1 transmission: implications for the design of prevention and treatment interventions.关于HIV-1传播的系统发育推断：对预防和治疗干预措施设计的启示。
AIDS. 2013 Apr 24;27(7):1045-57. doi: 10.1097/QAD.0b013e32835cffd9.
8
A case of apparent resistance to all available antiretroviral drugs in a HIV-positive patient.一名HIV阳性患者对所有可用抗逆转录病毒药物出现明显耐药的病例。
Sex Health. 2010 Mar;7(1):82-4. doi: 10.1071/SH09032.
9
The probable source of both the primary multidrug-resistant (MDR) HIV-1 strain found in a patient with rapid progression to AIDS and a second recombinant MDR strain found in a chronically HIV-1-infected patient.在一名迅速进展为艾滋病的患者中发现的原发性多药耐药（MDR）HIV-1毒株以及在一名慢性HIV-1感染患者中发现的第二种重组MDR毒株的可能来源。
J Infect Dis. 2007 May 1;195(9):1250-9. doi: 10.1086/512240. Epub 2007 Mar 21.
10
Seroconversion on preexposure prophylaxis: a case report with segmental hair analysis for timed adherence determination.暴露前预防的血清转化：一份通过分段头发分析来确定定时依从性的案例报告。
AIDS. 2018 Jun 1;32(9):F1-F4. doi: 10.1097/QAD.0000000000001825.
引用本文的文献
1
Assessment of the Impact of Gender, Age, Sexual Orientation and PrEP on HIV Infection: Analysis of Anonymous HIV Tests of People in Voluntary Counselling and Testing Points (VCTs) in Poland in 2015-2023.性别、年龄、性取向及暴露前预防对艾滋病毒感染影响的评估：对2015年至2023年波兰自愿咨询检测点（VCTs）人群匿名艾滋病毒检测的分析
AIDS Behav. 2025 Apr 5. doi: 10.1007/s10461-025-04701-2.
2
Oral HIV pre-exposure prophylaxis use and resistance-associated mutations among men who have sex with men and transgender persons newly diagnosed with HIV in the Netherlands: results from the ATHENA cohort, 2018 to 2022.荷兰新诊断 HIV 感染的男男性行为者和跨性别者中口服 HIV 暴露前预防用药使用情况和耐药相关突变：来自 ATHENA 队列的研究，2018 年至 2022 年。
Euro Surveill. 2024 Sep;29(38). doi: 10.2807/1560-7917.ES.2024.29.38.2400083.
3
Breakthrough Acute HIV Infections among Pre-Exposure Prophylaxis Users with High Adherence: A Narrative Review.突破性急性 HIV 感染在高依从性的暴露前预防用药者中的发生：一项叙述性综述。
Viruses. 2024 Jun 12;16(6):951. doi: 10.3390/v16060951.
4
Rational Design and Characterization of Trispecific Antibodies Targeting the HIV-1 Receptor and Envelope Glycoprotein.靶向HIV-1受体和包膜糖蛋白的三特异性抗体的合理设计与表征
Vaccines (Basel). 2023 Dec 23;12(1):19. doi: 10.3390/vaccines12010019.
5
Undeclared pre-exposure or post-exposure prophylaxis (PrEP/PEP) use among syphilis-positive blood donors, England, 2020 to 2021.2020 年至 2021 年，英格兰梅毒阳性献血者中未经申报的暴露前或暴露后预防（PrEP/PEP）使用情况。
Euro Surveill. 2023 Mar;28(11). doi: 10.2807/1560-7917.ES.2023.28.11.2300135.
6
Clinical Considerations in the Selection of Preexposure Prophylaxis for HIV Prevention in Canada.加拿大预防艾滋病病毒暴露前预防用药选择的临床考量
Can J Infect Dis Med Microbiol. 2022 Aug 30;2022:3913439. doi: 10.1155/2022/3913439. eCollection 2022.
7
A public health approach to monitoring HIV with resistance to HIV pre-exposure prophylaxis.采用公共卫生方法监测对 HIV 暴露前预防具耐药性的 HIV。
PLoS One. 2022 Aug 29;17(8):e0272958. doi: 10.1371/journal.pone.0272958. eCollection 2022.
8
Am I Positive? Improving Human Immunodeficiency Virus Testing in the Era of Preexposure Prophylaxis and Immediate Antiretroviral Therapy Using Machine Learning.我呈阳性吗？利用机器学习在暴露前预防和即时抗逆转录病毒治疗时代改进人类免疫缺陷病毒检测
Open Forum Infect Dis. 2022 May 18;9(7):ofac259. doi: 10.1093/ofid/ofac259. eCollection 2022 Jul.
9
Casting a Wide Net: HIV Drug Resistance Monitoring in Pre-Exposure Prophylaxis Seroconverters in the Global Evaluation of Microbicide Sensitivity Project.广泛撒网：在全球杀微生物剂敏感性项目中，对暴露前预防血清转换者中的 HIV 耐药性监测。
Glob Health Sci Pract. 2022 Apr 29;10(2). doi: 10.9745/GHSP-D-21-00122. Print 2022 Apr 28.
10
HIV-1-infection in a man who has sex with men despite self-reported excellent adherence to pre-exposure prophylaxis, the Netherlands, August 2021: be alert to emtricitabine/tenofovir-resistant strain transmission.2021 年 8 月，荷兰一名男男性行为者尽管自述对暴露前预防措施的依从性极好，但仍感染了 HIV-1：警惕恩曲他滨/替诺福韦耐药株传播。
Euro Surveill. 2022 Apr;27(14). doi: 10.2807/1560-7917.ES.2022.27.14.2200275.
本文引用的文献
1
Multidrug-Resistant HIV-1 Infection despite Preexposure Prophylaxis.尽管进行了暴露前预防但仍出现多重耐药HIV-1感染
N Engl J Med. 2017 Feb 2;376(5):501-502. doi: 10.1056/NEJMc1611639.
2
Association of age, baseline kidney function, and medication exposure with declines in creatinine clearance on pre-exposure prophylaxis: an observational cohort study.年龄、基线肾功能和药物暴露与暴露前预防中肌酐清除率下降的关联：一项观察性队列研究。
Lancet HIV. 2016 Nov;3(11):e521-e528. doi: 10.1016/S2352-3018(16)30153-9. Epub 2016 Aug 31.
3
Initiation of Antiretroviral Therapy During Acute HIV-1 Infection Leads to a High Rate of Nonreactive HIV Serology.急性 HIV-1 感染时启动抗逆转录病毒治疗可导致高比例的 HIV 血清学无反应。
Clin Infect Dis. 2016 Aug 15;63(4):555-61. doi: 10.1093/cid/ciw365. Epub 2016 Jun 17.
4
Effectiveness and safety of oral HIV preexposure prophylaxis for all populations.针对所有人群的口服HIV暴露前预防的有效性和安全性。
AIDS. 2016 Jul 31;30(12):1973-83. doi: 10.1097/QAD.0000000000001145.
5
Preexposure Prophylaxis for HIV Infection Integrated With Municipal- and Community-Based Sexual Health Services.与市级和社区性健康服务相结合的HIV感染暴露前预防
JAMA Intern Med. 2016 Jan;176(1):75-84. doi: 10.1001/jamainternmed.2015.4683.
6
Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial.暴露前预防以预防HIV-1感染（PROUD）：一项实用开放标签随机试验试点阶段的有效性结果
Lancet. 2016 Jan 2;387(10013):53-60. doi: 10.1016/S0140-6736(15)00056-2. Epub 2015 Sep 9.
7
Pharmacological Measures of Treatment Adherence and Risk of HIV Infection in the VOICE Study.VOICE研究中治疗依从性的药理学措施与HIV感染风险
J Infect Dis. 2016 Feb 1;213(3):335-42. doi: 10.1093/infdis/jiv333. Epub 2015 Jun 29.
8
Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study.男男性行为者和男变女性别者中暴露前预防措施的采用情况、性行为及艾滋病毒发病率：一项队列研究
Lancet Infect Dis. 2014 Sep;14(9):820-9. doi: 10.1016/S1473-3099(14)70847-3. Epub 2014 Jul 22.
9
Estimating per-act HIV transmission risk: a systematic review.估计单次行为的HIV传播风险：一项系统评价。
AIDS. 2014 Jun 19;28(10):1509-19. doi: 10.1097/QAD.0000000000000298.
10
HIV protective efficacy and correlates of tenofovir blood concentrations in a clinical trial of PrEP for HIV prevention.在一项用于预防 HIV 的 PrEP 临床试验中，替诺福韦的血液浓度与 HIV 保护效果及相关因素。
J Acquir Immune Defic Syndr. 2014 Jul 1;66(3):340-8. doi: 10.1097/QAI.0000000000000172.
Zotero 插件